The role of anticoagulant therapy (warfarin) with antiplatelet therapy (aspirin) is a balance of risk versus benefit. However, reducing risk by de-prescribing is often avoided due to hypothetical efficacy reduction. Join host, Geoff Wall, as he evaluates de-prescribing aspirin in patients taking anticoagulants.
The GameChanger
Anticoagulant therapy provides as good or better protection against vascular outcomes as aspirin – creating duplication of therapy. The increased risk of bleeds may not outweigh the negligible efficacy benefit.
Are you looking for a place to network AND get some FREE CE? Download the CEimpact app. The app allows you to connect with pharmacy professionals, get CE, attend events, access product information and so much more - all from your mobile device.
Show Segments
00:00 - Introductions
00:58 - Aspirin Use with Anticoagulants
4:02 - Overview of Schafer et al
11:50 - The Gamechanger: Study Findings
17:48 - Connecting to Practice: DOAC Use
19:52 - Closing Remarks
Host
Geoff Wall, PharmD, BCPS, FCCP, CGP
Professor of Pharmacy Practice, Drake University
Internal Medicine/Critical Care, UnityPoint Health
References and Resources
Redeem your CPE or CME here
Get a membership & earn CE for GameChangers Podcast episodes (30 mins/episode)
CE Information
Learning Objectives
Upon successful completion of this knowledge-based activity, participants should be able to:
1. Discuss indications for cardioprotective aspirin in patients taking anticoagulants
2. Describe drawbacks to implementing the findings of the Schaefer et al study to a general patient population using anticoagulants
0.05 CEU/0.5 Hr
UAN: 0107-0000-22-381-H01-P
Initial release date: 10/24/2022
Expiration date: 10/24/2023
Additional CPE and CME details can be found here